Redefining Synthetic Lethality

Tessellate BIO is redefining synthetic lethality in cancer beyond homologous recombination deficiency

Our vision

Our vision is to redefine synthetic lethality, turning cancer patients into cancer survivors.

Truly pioneering approach to synthetic lethality: tackling the areas of highest medical need through new targets beyond HRD

Driven by profound scientific understanding: leading scientists as founders and key strategic advisors

A ‘drug hunter’ model: bringing together best international science and proven drug development experience to create first-in-class pipeline

Tumor agnostic: dependent on cancer genotype or phenotype rather than tissue of action

Committed to precision medicine: companion diagnostics are integral, not an add-on

An excellent blend of pharma and biotech R&D experience with a proven track record of drug development from patent to patient.

We’re building a pipeline of first-in-class medicines based on cutting-edge research, sourced from international world-renowned laboratories

Stay up to date with our latest developments here

We’re expanding – join us on this exciting journey!

Gooimeer 2-35 | 1411 DC Naarden | The_Netherlands
Privacy Policy – Terms & Conditions – Cookie policy

Tessellate Bio is a registered trademark of Tessellate Bio BV